Cogent Biosciences

Cogent Biosciences is a biotechnology company focused on the discovery, development and commercialization of precision therapies for genetically defined diseases. According to its own materials, the company designs rational precision therapies that target the underlying genetic drivers of disease rather than only treating symptoms, with the goal of delivering best-in-class small-molecule therapeutics for cancers, autoimmune conditions and rare diseases where significant unmet need remains. Its stated philosophy is to start "with the end in mind" and to focus on diseases whose cause is well understood and directly linked to a genetic mutation. The company's lead drug candidate is bezuclastinib, a highly selective and potent inhibitor of KIT exon 17 mutations, including KIT D816V. This mutation keeps the KIT receptor tyrosine kinase in a perpetual "on" state, causing mast cells to accumulate in internal organs such as the bone marrow and producing the orphan disease systemic mastocytosis (SM). The same class of mutations is found in advanced gastrointestinal stromal tumors (GIST), which depend strongly on oncogenic KIT signaling. Cogent positions bezuclastinib as a potential new treatment option for both nonadvanced and advanced systemic mastocytosis as well as GIST. Cogent describes a broad portfolio of novel agents spanning hematology and oncology, reflecting an ability to discover and advance targeted therapies. The company has built a discovery organization in Boulder, Colorado, dedicated to pioneering small-molecule therapeutics intended to improve on existing drugs that have clear limitations or safety concerns. Its pipeline strategy centers on validated biology and rational drug design. Leadership includes Andrew Robbins as Chief Executive Officer and President, Jessica Sachs, MD, as Chief Medical Officer, Cole Pinnow as Chief Commercial Officer, John Robinson, PhD, as Chief Scientific Officer, Brad Barnett as Chief Technology Officer, Erin Schellhammer as Chief People Officer, Evan Kearns, JD, as Chief Legal Officer and Corporate Secretary, and John Green as Chief Financial Officer. The board includes representatives of Fairmount Funds Management LLC alongside independent pharma-biotech executives. Cogent Biosciences is a publicly traded company based in Waltham, Massachusetts, with a research presence in Boulder, Colorado. Its recent news includes FDA acceptance of a New Drug Application (NDA) for bezuclastinib in patients with advanced systemic mastocytosis, announced in September 2026 according to the company's website. The company continues to position itself around precision therapies for patients with genetically defined diseases and unmet medical needs.

Cogent Biosciences is a biotechnology company based in Waltham, Massachusetts, with a discovery organization in Boulder, Colorado. Public records describe it as a company in Waltham, United States. The company has positioned itself around the design of rational precision therapies for genetically defined diseases, focusing on diseases whose cause is well understood and directly linked to a genetic mutation. Cogent's stated approach is to identify pragmatic solutions to complex health challenges, moving beyond incremental improvements and symptom-only treatment to address the underlying causes of disease. It aims to discover, develop and commercialize best-in-class therapies that have a dramatic impact for patients with genetically defined diseases. The company has built a world-class discovery organization in Boulder, Colorado, focused on pioneering best-in-class small-molecule therapeutics intended to improve upon existing drugs with clear limitations and safety concerns. The company's lead drug candidate is bezuclastinib, a highly selective and potent KIT inhibitor designed to target exon 17 mutations within the KIT receptor tyrosine kinase, including KIT D816V. This mutation keeps KIT in a perpetual "on" state, causing mast cells to accumulate in internal organs such as the bone marrow and producing systemic mastocytosis (SM), an orphan disease. Exon 17 mutations are also found in advanced gastrointestinal stromal tumors (GIST), which have a strong dependence on oncogenic KIT signaling. Cogent is developing bezuclastinib as a potential treatment option for patients with both diseases. Cogent describes a broad portfolio of novel agents demonstrating its ability to discover and advance targeted therapies in both hematology and oncology. Its pipeline strategy centers on validated biology and rational drug design, with the goal of creating new breakthroughs for diseases where others have been unable to find adequate solutions. Leadership includes Andrew Robbins as Chief Executive Officer and President, Jessica Sachs, MD, as Chief Medical Officer, Cole Pinnow as Chief Commercial Officer, John Robinson, PhD, as Chief Scientific Officer, Brad Barnett as Chief Technology Officer, Erin Schellhammer as Chief People Officer, Evan Kearns, JD, as Chief Legal Officer and Corporate Secretary, and John Green as Chief Financial Officer. The board of directors includes Peter Harwin, Founding Partner of Fairmount Funds Management LLC; Chris Cain, Director of Research at Fairmount Funds Management LLC; Karen Ferrante, MD, a medical oncologist and former pharma-biotech executive; Arlene M. Morris, Chief Executive Officer of Willow Advisors; Matthew E. Ros, a pharma-biotech executive; Todd E. Shegog, a pharma-biotech executive; and Andrew Robbins. In September 2026, Cogent Biosciences announced FDA acceptance of a New Drug Application (NDA) for bezuclastinib in patients with advanced systemic mastocytosis (AdvSM), a significant regulatory milestone for the company's lead candidate. The company continues to be driven by the patients it serves and is committed to delivering novel precision therapies to patients with unmet medical needs.

• Cogent Biosciences announces FDA acceptance of a New Drug Application (NDA) for bezuclastinib in patients with advanced systemic mastocytosis (AdvSM).

Clinical-stage biotechnology company developing best-in-class precision small-molecule therapies for genetically defined diseases.

• Bezuclastinib

  Lead drug candidate; a highly selective and potent KIT inhibitor targeting exon 17 mutations including KIT D816V, being developed for systemic mastocytosis and advanced gastrointestinal stromal tumors (GIST).

1. 1Cogent Biosciencescogentbio.com
2. 2About – Cogent Biosciencescogentbio.com
3. 3Bezuclastinib – Cogent Biosciencescogentbio.com
4. 4Bezuclastinib – Cogent Biosciencescogentbio.com
5. 5Cogent Biosciences (United States) – Wikidatawikidata.org
6. 6Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stockprnewswire.com
7. 7Cogent Biosciences Appoints Andrew Robbins as Chief Executive Officerbiospace.com